Invengene Private Limited has been named Pharma Startup of the Year at the FE Pharma Awards & Summit 2026, held in New Delhi on March 19, 2026. The award was presented by Roshun Povaiah, Editor – FE Digital, recognising the company’s focused approach to building a differentiated pharmaceutical business.

The recognition reflects Invengene’s work in advancing injectable product development through strong formulation science, disciplined execution, and a partnership-led model. In a short span, the company has built a growing portfolio of complex injectables with a clear emphasis on accessibility, scalability, and multi-market applicability.

Ankur Shah, Chairman & Managing Director, Invengene, said:
“This recognition reflects the direction we are building towards focused science, disciplined execution, and a clear intent to improve access to essential therapies. It reinforces our belief that consistent, thoughtful execution creates long-term impact.”

Invengene operates with an asset-light, globally integrated model, working with qualified manufacturing partners while maintaining oversight across development, regulatory strategy, and commercialisation.

This recognition marks another step in Invengene’s journey as it continues to build with purpose of Simplifying Science, Together.